Quick Answer
Lexaria Bioscience Corp. reported Cash and Equivalents of $5.81 million for fiscal year 2022.
Lexaria Bioscience Corp. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2022 | $5.81M | -46.8% |
| 2021 | $10.92M | +743.9% |
| 2020 | $1.29M | +0.7% |
| 2019 | $1.29M | -25.6% |
| 2018 | $1.73M | -31.8% |
| 2017 | $2.53M | +2612.1% |
| 2016 | $93.4K | -64.1% |
| 2015 | $260.1K | -63.0% |
| 2014 | $703.0K | +972.6% |
| 2013 | $65.5K | +0.0% |
| 2013 | $65.5K | -63.7% |
| 2012 | $180.5K | +478.6% |
| 2011 | $31.2K | -50.5% |
| 2010 | $63.0K | -80.9% |
| 2009 | $330.2K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| February 28, 2023 | $3.27M | -60.9% | -27.8% |
| November 30, 2022 | $4.53M | -53.2% | -22.0% |
| August 31, 2022 | $5.81M | -46.8% | -17.6% |
| May 31, 2022 | $7.05M | -13.0% | -15.7% |
| February 28, 2022 | $8.36M | -10.6% | -13.7% |
| November 30, 2021 | $9.68M | +1743.0% | -11.3% |
| August 31, 2021 | $10.92M | +743.9% | +34.6% |
| May 31, 2021 | $8.11M | +298.6% | -13.2% |
- Lexaria Bioscience Corp. showed a decrease of -46.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2022 period, Lexaria Bioscience Corp.’s cash and equivalents has grown by 1660.7% (from $330.2 thousand to $5.81 million).
- The most recent figure is from Lexaria Bioscience Corp.’s fiscal year 2022 report (Form 10-K), filed with the SEC on November 28, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: